ClinicalTrials.Veeva

Menu
P

Precision Comprehensive Clinical Research Solutions | PCCR Solutions - Dr. Basu

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

BIIB059
Litifilimab
Guselkumab
Obinutuzumab
M5049
Zetomipzomib
Efavaleukin Alfa
VIB7734
KZR-616

Parent organization

This site is a part of Precision Comprehensive Clinical Research Solutions

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 13 total trials

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)

The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active pso...

Active, not recruiting
Psoriatic Arthritis
Biological: Placebo
Biological: Risankizumab

The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (Ps...

Active, not recruiting
Psoriatic Arthritis (PsA)
Biological: Placebo
Biological: Risankizumab

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by...

Enrolling
Arthritis, Psoriatic
Drug: Placebo
Drug: Guselkumab

The purpose of this study is to evaluate the efficacy of nipocalimab versus placebo in participants with active systemic lupus erythematosus (SLE).

Active, not recruiting
Systemic Lupus Erythematosus
Other: Placebo
Drug: Standard-of-care treatment
Locations recently updated

The purpose of this study is to assess the efficacy and safety of zetomipzomib (30 mg or 60 mg) compared with placebo in achieving renal response aft...

Enrolling
Lupus Nephritis
Drug: placebo
Drug: zetomipzomib

The primary objectives of the study are to evaluate the efficacy of BIIB059 (litifilimab) compared with placebo in reducing skin disease activity mea...

Enrolling
Subacute Cutaneous Lupus Erythematosus
Chronic Cutaneous Lupus Erythematosus
Drug: BIIB059 (litifilimab)
Drug: Placebo

The primary objective of this study is to evaluate the long-term safety and tolerability of litifilimab in participants with active systemic lupus er...

Invitation-only
Systemic Lupus Erythematosus (SLE)
Drug: Litifilimab-matching placebo
Drug: Litifilimab

This parallel-group, double-blind, placebo-controlled study will evaluate the efficacy and safety of obinutuzumab versus placebo in participants with...

Enrolling
Systemic Lupus Erythematosus
Drug: Methylprednisolone
Drug: Acetaminophen/Paracetamol

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) and inadequate re...

Enrolling
Arthritis, Psoriatic
Drug: Placebo
Drug: Guselkumab

The purpose of this Proof of Concept (PoC) and Dose-finding (DF) basket study is to evaluate the efficacy and safety of orally administered Enpatoran...

Active, not recruiting
Systemic Lupus Erythematosus
Drug: Enpatoran low dose
Drug: Placebo

Trial sponsors

Amgen logo
Janssen (J&J Innovative Medicine) logo
AbbVie logo
Biogen logo
K
Merck KGaA (EMD Serono) logo
Roche logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems